Opus Genetics
IRD
36 hedge funds and large institutions have $5.61M invested in Opus Genetics in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 5 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
33% more funds holding
Funds holding: 27 → 36 (+9)
6% more capital invested
Capital invested by funds: $5.27M → $5.61M (+$341K)
0.16% more ownership
Funds ownership: 8.35% → 8.51% (+0.16%)
35% less call options, than puts
Call options by funds: $26K | Put options by funds: $40K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.63M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$294K |
| 3 |
State Street
Boston,
Massachusetts
|
+$271K |
| 4 |
Goldman Sachs
New York
|
+$185K |
| 5 |
BlackRock
New York
|
+$160K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$2.31M |
| 2 |
Renaissance Technologies
New York
|
-$388K |
| 3 |
PVI
Pura Vida Investments
New York
|
-$334K |
| 4 |
Millennium Management
New York
|
-$74K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $30K | +$18.5K | +3,732 | +206% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $17K | +$3.89K | +784 | +31% |
|
28
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $7K | +$6.95K | +1,400 | New |
|
29
First Manhattan
New York
| $3K | – | – | – |
|
|
ACM
30
Altium Capital Management
New York
| – | -$2.31M | -397,036 | Closed |
|
|
PVI
31
Pura Vida Investments
New York
| – | -$334K | -57,536 | Closed |
|
|
32
Millennium Management
New York
| – | -$74K | -12,692 | Closed |
|
|
33
Acadian Asset Management
Boston,
Massachusetts
| – | -$13K | -2,174 | Closed |
|
|
SPIA
34
Steward Partners Investment Advisory
New York
| – | -$87 | -15 | Closed |
|
|
SIC
35
Salem Investment Counselors
Winston Salem,
North Carolina
| – | +$50 | +10 | New |
|
IRD Hedge Fund Activity: Q2 2021 in Review
36 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q2 2021, worth a combined $5.61M — up 6.5% from $5.27M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IRD positions and 5 closed out — a net gain of 9 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $1.63M. The largest seller was Altium Capital Management, exiting entirely with an estimated $2.31M sold.
- 36 institutional investors held Opus Genetics (IRD) as of Q2 2021, up from 27 in Q1 2021.
- Funds reported $5.61M of Opus Genetics stock for Q2 2021, up 6.5% quarter-over-quarter.
- 14 funds opened new Opus Genetics positions in Q2 2021 and 5 closed out, a net change of +9 holders.
- The largest Opus Genetics buyer in Q2 2021 was Marshall Wace, an estimated $1.63M added.
- The largest Opus Genetics seller in Q2 2021 was Altium Capital Management, an estimated $2.31M sold.
Based on aggregated 13F filings for Q2 2021.